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Olfactory ensheathing cells (OECs) are a special type of glial cell in the
olfactory system, which exhibit neuroprotective, immunomodulatory,
and angiogenic effects. Although many studies have focused on the
reversal of demyelination and axonal degeneration (during spinal cord
injury) by OECs, few reports have focused on the ability of OECs to
repair ischemic nerve injury. This article reviews the protective effects of
OEC transplantation in ischemic stroke and provides a theoretical basis
and new strategy for OEC transplantation in the treatment of ischemic
stroke.

© The authors 2021. This article
is published with open access at
http://jnr.tsinghuajournals.com

KEYWORDS
ischemic stroke;
olfactory ensheathing cells;
cell therapy;
cerebrovascular disease

1

Introduction

Ischemic stroke is a major cause of death and
long‐term disability, resulting in a high social
and economic burden [1]. There is a strict time
window for thrombolysis or mechanical
thrombectomy in the acute stage, and patients
who fail to receive treatment develop lifelong
disabilities [2]. The current methods for treating
ischemic stroke are less effective with respect to
neurogenesis and functional recovery in the
chronic phase, which adversely affects the life
and socioeconomic status of patients. Thus,
nerve regeneration methods are being deve‐
Correspondence author: Jianhua Zhao, Email: 051092@xxmu.edu.cn

loped to promote the repair of damaged neural
networks and reduce the risk of disability
caused by ischemic stroke [3]. Cell therapy is
effective in acute, subacute, and chronic stroke
[4] and represents a new therapeutic strategy for
the treatment of ischemic stroke. Animal studies
have shown that cell therapy may improve
neurological dysfunction following stroke and it
has been tested in clinical trials with somewhat
favorable results [5–8]. However, many issues
remain unresolved and require clarification,
such as the need to develop techniques that
maximally enhance the effects of cell therapy
on stroke. These issues relate to defining the
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optimal cell types, cell doses, transplantation
routes, and candidate patient types. The specific
efficacy of each of these factors also needs to be
confirmed. Many studies have demonstrated
that neural stem cells (NSCs) [9–11], human
umbilical cord blood cells [12–14], bone marrow
mononuclear cells [15–17], hematopoietic stem
cells, bone marrow/adipose‐derived mesenchymal
stem cells/stromal cells [18–21], Schwann cells,
mesenchymal cells, and other stem cells exhibit
tissue remodeling activity in animal models of
ischemic stroke injury. However, the survival
rate of these cells and their integration into the
host tissue after transplantation remain poor. A
previous study showed that olfactory ensheath‐
ing cells (OECs) have a stronger ability to inhibit
glial scar formation and the inflammatory
response of astrocytes in spinal cord injury than
Schwann cells [22]. They also promoted the
growth of nerve axons and established synapses
between nerve axons. Several clinical studies
[23–27] have also shown that patients with
spinal cord injury who received fetal olfactory
bulb (OB) or autologous olfactory mucosa (OM)
OEC transplantation showed improvement of
varying degrees in motor and sensory function.
However, it is not clear whether the effects of
OEC transplantation can play a role in ischemic
stroke and spinal cord injury. This review
describes the pathological mechanism of
ischemic stroke, the characteristics of OECs, and
the role of OEC transplantation in ischemic
stroke. It provides a theoretical basis for treating
tissue injury after focal cerebral ischemia and
the potential of OEC transplantation for the
treatment of ischemic stroke.

2

Pathophysiology of ischemic stroke

Stroke is usually caused by a single vascular
occlusion that affects downstream processes by
deprivation of glucose and oxygen. Although

the cerebral artery has a collateral vascular
network to compensate, it is usually not
sufficient to save the entire ischemic area.
Therefore, the closer the ischemic area is to the
occluded vessel, the less blood passes through.
Inflammation is an important mechanism of
secondary nerve injury in ischemic stroke.
Astrocytes are widely distributed in the brain,
exhibit strong tolerance to hypoxia, and can
interact with almost all cells of the neuro‐
vascular units. Astrocytes are rapidly activated
into reactive astrocytes after ischemic stroke,
releasing inflammatory factors and promoting
the activation and invasion of other
inflammatory cells. This triggers an inflammatory
response cascade and aggravates ischemic nerve
injury. Inflammatory cascades triggered by
cellular ischemic events include primarily
impaired cellular energy metabolism, cellular
depolarization, excitotoxicity, and blood–brain
barrier disruption [22]. Theoretically, the
ischemic brain can be divided into two diverse
harmed locales, specifically, the ischemic center
and the penumbra. The ischemic cascade in the
ischemic penumbra advances over time. The
events include adenosine triphosphate exhaus‐
tion; disturbance of sodium, potassium, and
calcium concentrations; increased lactic corrosion;
acidosis; increased oxygen free radicals;
discharge of excitatory glutamate; and increased
intracellular water that may occur from a couple
of minutes to hours after a stroke occurs. Inside
hours to weeks (subacute phase), neuronal
apoptosis, penetration and actuation of
inflammatory cells (neutrophils, monocytes, and
microglia), angiogenic edema, and elevated
intracranial pressure begin to occur. Despite
ischemia, the pathological response of the brain
appears to be stable after entering the chronic
phase, but the irritation and blood–brain
boundary spillage, which are not conducive to
the recovery of the brain, may continue,
Journal of Neurorestoratology
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resulting in serious consequences to the body
[28]. The injury pathways secondary to ischemic
stroke are presented in detail in Fig. 1 [29]. Since
the bloodstream within the ischemic center is
lower than the level required for cell survival,
the cells die, resulting in irreversible damage. In
the event the blood flow in the ischemic
penumbra decreases and cannot support
neurological function, it provides the minimum
energy needed to prevent immediate cell death.
If the blood flow recovers in time [30], brain cell
injury is reversible.

3

Potential mechanism of cell therapy for
ischemic stroke

In view of the pathophysiological mechanism of
ischemic stroke, the current treatment strategy
of cell transplantation is primarily designed to
save reversibly damaged cells in the ischemic
penumbra or to restore a new neural network
through cell transplantation [31]. Cell therapy

Fig. 1
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has multiple effects in animal models of
ischemic stroke, such as prolonging the ischemic
penumbra (acute phase), inhibiting unnecessary
inflammation (subacute phase), and initiating
neuroangiogenesis in the chronic phase. This
provides an option to expand the treatment
window for cerebral infarction stenosis and, at
the same time, ameliorates the key components
of stroke pathophysiology, which is cell loss
caused by ischemia. As outlined in several
descriptive reviews [3, 32–34], these mechanisms
can be subdivided into two categories: (i) cell
differentiation (cell substitution), and (ii)
secretion of paracrine factors (bystander effect).
Cell substitution can restore lost function by
differentiating the transplanted cells into
neurons or vascular cells, or through the direct
settlement and development of neural pro‐
genitor cells (NPCs). An in vivo study showed
that 2 months after cell transplantation,
approximately 50% of the transplanted cells
displayed a neuronal phenotype in the ischemic

The injury pathways secondary to ischemic stroke. Reproduced from Ref. [29].
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brain [35]. In addition, cell substitution can
enhance the expression of neural genes related
to the release of nutritional factors. The release
of paracrine factors is another potential
mechanism of cell transplantation therapy,
which occurs primarily through the secretion of
a variety of nutritional factors (cytokines,
chemokines, exocrine bodies) that contribute to
anti‐inflammation, immune regulation, and
mobilization of endogenous stem cell (NSC)/
NPCs [36].

4

Biological characteristics of OECs

OECs are a special type of glial cell that have the
properties of both Schwann cells and astrocytes.
OECs can accompany olfactory nerve axons
from the peripheral nervous system to the
central nervous system and combine with the
mitral cells of the OB at the skull base [37]. OECs
are the only known glial cells that can cross the
barrier between the peripheral and central
nerves, and have the ability to regenerate at a
mature stage. OECs exhibit a faster proliferation
rate in culture and have the potential for various
applications. In addition to spinal cord injuries,
they may be used for the treatment of
cerebrovascular and ophthalmological diseases
[38]. OECs are considered to be the key to the
lifelong regeneration of the primary olfactory
nervous system. Therefore, the transplantation
of OECs to repair the damaged nervous system
has been a focus of research over the past two
decades [39–41]. In the natural environment,
OECs support and guide the extension from the
OM to the target synaptic area of the OB [42].
This promotes nerve regeneration at the
anatomical location as well as after transplanta‐
tion. The mechanism mainly includes direct
interaction with surrounding axons and support
structures, secretion of neurotrophic and guide

factors [43, 44], phagocytosis of axonal
fragments, and effective migration and
integration with other types of cells, such as
astrocytes and microglia [45, 46].

5

The principle of OECs in the treatment
of ischemic stroke

Different stages of the ischemic process provide
different targets for OEC therapy. Early
application of OECs can reduce inflammation,
regulate the dynamic environment of anti‐
toxicity, and reduce injury to the infarcted area.
Two or 3 weeks after ischemia, late cell
transplantation can regulate the repair process,
which is beneficial to angiogenesis and nerve
regeneration. As described in many experiments
[47–50], vascular endothelial growth factor,
brain‐derived neurotrophic factor, glial cell
line‐derived neurotrophic factor, and nerve
growth factor, secreted by OECs, play an
important role in the function of nerves, glia,
and endothelial cells [51, 52]. They have
significant potential in promoting brain
plasticity and functional recovery. In addition,
Nazareth et al. showed that OECs exhibit higher
phagocytosis and transport activity than
Schwann cells and have a stronger inhibitory
effect on inflammation [53]. OECs are different
from astrocytes and Schwann cells, but they
exhibit characteristics of both. OECs are similar
to Schwann cells in promoting axon growth, but
they are more likely to promote axon growth
over long distances than Schwann cells; that is,
they are more migratory. As astrocytes, OECs
also contribute to neuronal survival and axonal
growth. OECs have no myelin, but they can
wrap around neurons to form a myelin sheath
and support neurite growth after transplanta‐
tion into the central nervous system. These
characteristics enable OECs to have a superior
therapeutic effect on nerve repair.
Journal of Neurorestoratology
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OEC transplantation pathway and dose

OEC transplantation is generally performed
through intracranial and intravascular methods.
Most strategies of intracranial injection are done
by intracerebral injection and intraventricular
injection [54]. Stereotactic injection makes a
difference in transporting OECs directly to the
infarcted zone, but requires preciseness to reach
the target area [55]. Intracerebroventricular
infusion disseminates OECs to a more extensive
range in the brain, and the level of inflammatory
cytokines increases after dead tissue absorbs
OECs to the center of the ischemic range. Thus,
the restorative impact depends on the number
of cells entering the infarcted region [56].
Strategies for intravascular infusion include
intravenous and intra‐arterial infusion. OECs
injected intravenously have difficultly passing
through pneumonic vessels because of their size;
thus, few cells reach the target area [57]. Inner
carotid supply route infusion can deliver OECs
in a short period; however, intra‐arterial
infusion may lead to peripheral cerebral artery
occlusion [58]. Intracranial transplantation may
cause mechanical harm, but it can transport cells
to the target location more efficiently than other
strategies. Intravascular transplantation requires
more cells than intracranial transplantation and
has a better therapeutic effect on large areas of
infarction. In clinical applications, endovascular
therapy is easier to perform than intracranial
therapy. Nasal injection (IN) is a new method of
transplantation, which needs further study [59].
Cells may be transported from the nasal mucosa
to the injured area through the blood circulation
[60]. As a non‐invasive method, IN represents a
promising new method of cell transplantation
[61, 62]. OEC treatment could be a new strategy
for neuroprotection against intense ischemic
stroke. Although there have been trials of OECs
in the treatment of ischemic stroke, there is still
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no consensus on the optimal dose for cell
therapy. In addition, it is still unknown whether
the dose of OECs should be personalized based
on the size of the infarction [63].

7

Research on OEC transplantation in
ischemic stroke

There are few studies describing the effect of
OEC transplantation on ischemic stroke. In this
review, the literature related to several trials
involving OEC transplantation in the treatment
of ischemic stroke was obtained from PubMed,
CNKI, Wanfang Data, and VIP Chinese journal
databases, whereas the search language was
unlimited. The keywords searched in the
Chinese database were “olfactory ensheathing
cell”, “ischemic stroke”, and “cerebral infarc‐
tion”. The keywords for the PubMed database
were “olfactory ensheathing cell”, “ischemic
stroke”, and “OECs”. The searches were limited
to “Title” and “Abstract”. Five papers were
identified, including one clinical trial and four
basic research studies. The dosage, pathway,
and source of OECs used in each trial were
slightly different as shown in Table 1. However,
through a comprehensive analysis of the
experiments, we found that OEC transplantation
is feasible and effective in the treatment of
ischemic brain injury. Wang et al. found that
after cerebral ischemia–reperfusion, the score of
neurological deficit in the OEC transplantation
group was significantly lower than that in the
control group [64]. The pathological changes of
the injured brain tissue were significantly
alleviated, and the level of nerve cell
degeneration and necrosis was significantly
decreased, whereas interstitial edema was
alleviated. A large number of glial fibrillary
acidic protein and neurotrophin receptor
p75‐positive cells were observed in the infarcted
hemisphere in the cell transplantation
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Table 1

Published trials using OECs for ischemic stroke.

Reference

Subject

OECs source

Dose (cells)

Transplant timing

Route

[64]

Patients

OECs in an aborted fetus

5.0 × 10

12 months or more after ischemia

IN

[22]

Rat

OECs in newborn SD rats

3.0 × 10

14 days after ischemia–reperfusion

IC

6
5

[65]

Rat

Human nasal polyps OECs

1.0 × 10

1 day after ischemia (no reperfusion)

IC

[66]

Rat

Transgenic rats OECs

5.0 × 105

Ischemia–reperfusion

IC

[67]

Patients

Fetal OECs

1.0 × 105

Sequelae of stroke or chronic phase

IC

5

IN, nasal injection; IC, intracerebral.

group. It was further verified that OECs can
improve the pathophysiological outcome of the
ischemic penumbra. Augestad et al. used a
middle cerebral artery occlusion (MCAO) model
to induce transient focal cerebral ischemia in
adult rats and found that OECs implanted into
the basal ganglia could promote tissue
remodeling [22]. Shyu et al. found that human
olfactory ensheathing cells/olfactory nerve
fibroblasts (hOECs/ONF) specifically secreted
nutritional factors, including stromal cell‐
derived factor‐1α [65]. The behavioral indices of
neurological impairment in stroke rats
implanted with hOEC/ONF were significantly
better than those in the control group. They
demonstrated that OESs induced nerve
regeneration and improved neurological dys‐
function caused by hypoxic and ischemic stress.
In another study, OECs promoted the repair of
white matter after transplantation in MCAO rats
[66]. Immediately after reperfusion, the
transplantation of OECs around the infarction
reduced the infarct volume, increased the
survival rate, and improved the neurological
defect. Immunohistochemical analysis showed
that this may be caused by myelin regeneration
and axon regeneration. The only clinical trial
included in our search showed that the
neurological function of patients receiving OEC
transplantation improved, including improved
speech, muscle strength, muscle tension, balance,
pain, and breathing [67]. The Barthel index and
clinical neurological deficit scores were

increased for most patients. However, because
of the small number of samples included in this
trial, the results of the study need to be further
verified in additional clinical studies. The above
results, though preliminary, indicate that a new
strategy based on OEC transplantation for the
treatment of ischemic stroke can be used at
different times following ischemic stroke, which
has certain benefits, although the safety profile
has not yet been established.

8

Perspect

Although the neuroprotective effect of OECs
on ischemic stroke has been preliminarily
confirmed, the specific protective mechanism
remains unclear. Many new strategies have been
proposed, including the use of cell transplanta‐
tion to support the internal repair and recovery
mechanisms, single drug administration and
combined transplantation, or combined trans‐
plantation of several cell types of cells and other
substances. However, these effects need to be
verified by well‐designed large‐scale trials. It is
necessary to clarify the mechanism of action in
cells following transplantation to better select
the optimal treatment time window for cell
transplantation, the best route for cells to enter
the brain, and more suitable cell types and
sources. This will enable patients to benefit from
treatment, monitor cell therapy by imaging
technology, and identify the best way to control
cell proliferation, survival, migration, and
Journal of Neurorestoratology

Journal of Neurorestoratology

differentiation in the pathological environment
[68, 69]. To optimize functional recovery,
neurorestorative therapy may require compre‐
hensive application [70–72]. Although there are
few studies on OECs for the treatment of
ischemic stroke and the related studies have
some limitations, the results indicate that OEC
therapy brings hope for patients with acute
stroke or chronic stroke sequelae. Therefore, it is
anticipated that it becomes a new treatment
option.
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